Steve,
Re: ENZN
As you mentioned, it has had insider's buying this Yr. (In March, Apr, May & especially in July & Aug before the Aug 21 spike <g>)
The stock is among the few Biotechs trying to stay on the green today in spite of the general market.(The picture of the DOW & the NAZ aren't bad, but the TRANS doesn't look as good.)
ENZN is showing a 57.36% gain from its Aug 14 L of $6.31 to the Oct 26 H of $9.93, so the insider aren't doing bad.<g>
bigcharts.marketwatch.com
On Oct 30 it announced the start of an open label PI of its EZN-2968, which is an HIF-1 alpha antagonist, to evaluate an additional dosing schedule & the safety, tolerability, and pharmacokinetics of EZN-2968 for 5 days in approximately 30 patients with advanced solid tumors or lymphoma.(EZN-2968 is among the HIF-1 alpha antagonists that it acquired from Santaris in July 2006 along with other product candidates created using the Locked Nucleic Acid technology platform, all directed against cancer targets.)
Also on Oct 30, it announced preclinical data showing that treatment with PEG-SN38, its PEGylated SN38 compound, resulted in significant tumor growth inhibition in mice with tumors resistant to Camptosar injection.
That data also demonstrated good in vitro activity of its Customized Linker Technology when applied to the LNA antagonists.(That data was presented at the American Association for Cancer Research-National Cancer Conference on "Molecular Targets and Cancer Therapeutics" in Frisco on Oct22)
Data from that study showed PEG-SN38 (EZN-2208) displayed potent in vitro cytotoxicity against a panel of human cancer cell lines and that it outperformed CPT-11 (Camptosar) in various preclinical cancer models including colorectal, breast, pancreatic, prostate, and lung cancers.
The stock made a 52 wks H on Oct 26 & it seems ready to test its April 2005 H at $10.21 but it has a good amount of resistance at the $11 level.
Although the loss on the 3rd Q were less than on the first 2Qs & at the same level of the 3rdQ in 2006, still the EL for 2007 is around $0.37/shr vs. the $0.01 on the black in 2006.
The stock has been forming a good base & is off its long term DT coming from its June 2001 H at 79.40 (as you may recall the rally from the Apr 2001 L of 39.56 wasn't able to test the Nov 2000 H of 84.12)
If it can deal with the resistance at the $11 level it seems it could get to the high teens.<g>
bigcharts.marketwatch.com
Bernard
|
